⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Monimoi Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Monimoi Therapeutics
↗Boston, USA
Monimoi Therapeutics is a biotechnology company focused on developing transformative cancer therapies by harnessing the potential of covalent medicines and chemical proteomics. The company integrates innovative covalent-based molecular technologies with deep human translational insights to target high-value, hard-to-drug cancer-promoting proteins and overcome resistance to existing treatments.
Founded in 2025 and headquartered in Boston, Massachusetts, Monimoi operates as a venture-backed startup. The company aims to widen the landscape of druggable targets to create durable treatments for cancer patients, supported by a network of prominent life science investors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Early Stage VC
Investors:The Column Group, Catalio Capital Management, Mass General Brigham Ventures, Regeneron Ventures, MHG Ventures
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery
Modalities:Small molecule, Covalent inhibitors
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Arnav Mehta - Co-Founder
LINKS
Website:monimoitx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Monimoi Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.